$304 Million is the total value of Iguana Healthcare Management, LLC's 64 reported holdings in Q4 2015. The portfolio turnover from Q3 2015 to Q4 2015 was 74.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| GILD | Sell | GILEAD SCIENCES INC | $9,107,000 | -7.3% | 90,000 | -10.0% | 3.00% | -22.4% |
| BIIB | Sell | BIOGEN INC | $6,127,000 | -30.0% | 20,000 | -33.3% | 2.02% | -41.4% |
| ESRX | Sell | EXPRESS SCRIPTS HLDG CO | $5,245,000 | -13.6% | 60,000 | -20.0% | 1.73% | -27.7% |
| LJPC | Sell | LA JOLLA PHARMACEUTICAL CO | $2,970,000 | -14.5% | 110,000 | -12.0% | 0.98% | -28.5% |
| NVDQ | Sell | NOVADAQ TECHNOLOGIES INC | $2,548,000 | -51.1% | 200,000 | -60.0% | 0.84% | -59.1% |
| VRX | Sell | VALEANT PHARMACEUTICALS INTL | $2,541,000 | -78.1% | 25,000 | -61.5% | 0.84% | -81.7% |
| MDVN | Sell | MEDIVATION INC | $2,417,000 | -18.8% | 50,000 | -28.6% | 0.80% | -32.1% |
| IPXL | Sell | IMPAX LABORATORIES INC | $2,138,000 | -19.0% | 50,000 | -33.3% | 0.70% | -32.3% |
| HZNP | Sell | HORIZON PHARMA PLC | $1,625,000 | -59.0% | 75,000 | -62.5% | 0.54% | -65.7% |
| WOOF | Sell | VCA INC | $825,000 | -73.9% | 15,000 | -75.0% | 0.27% | -78.2% |
| GENN | Sell | GENESIS HEALTHCARE INC | $347,000 | -68.5% | 100,000 | -44.4% | 0.11% | -73.7% |
| CBAY | Exit | CYMABAY THERAPEUTICS INC | $0 | – | -250,000 | -100.0% | -0.19% | – |
| MEIP | Exit | MEI PHARMA INC | $0 | – | -325,000 | -100.0% | -0.20% | – |
| MRNS | Exit | MARINUS PHARMACEUTICALS INC | $0 | – | -75,000 | -100.0% | -0.25% | – |
| Exit | NEVRO CORPcall | $0 | – | -15,000 | -100.0% | -0.27% | – | |
| ARWR | Exit | ARROWHEAD RESH CORP | $0 | – | -125,000 | -100.0% | -0.28% | – |
| DRNA | Exit | DICERNA PHARMACEUTICALS INC | $0 | – | -100,000 | -100.0% | -0.32% | – |
| Exit | SUPERNUS PHARMACEUTICALS INCcall | $0 | – | -65,000 | -100.0% | -0.36% | – | |
| IMDZ | Exit | IMMUNE DESIGN CORP | $0 | – | -75,000 | -100.0% | -0.36% | – |
| RVNC | Exit | REVANCE THERAPEUTICS INC | $0 | – | -35,000 | -100.0% | -0.41% | – |
| OCUL | Exit | OCULAR THERAPEUTIX INC | $0 | – | -75,000 | -100.0% | -0.42% | – |
| AERI | Exit | AERIE PHARMACEUTICALS INC | $0 | – | -60,015 | -100.0% | -0.42% | – |
| Exit | ESPERION THERAPEUTICS INC NEcall | $0 | – | -50,000 | -100.0% | -0.46% | – | |
| ESPR | Exit | ESPERION THERAPEUTICS INC NE | $0 | – | -50,000 | -100.0% | -0.46% | – |
| ZFGN | Exit | ZAFGEN INC | $0 | – | -40,000 | -100.0% | -0.50% | – |
| CNAT | Exit | CONATUS PHARMACEUTICALS INC | $0 | – | -300,000 | -100.0% | -0.52% | – |
| EPZM | Exit | EPIZYME INC | $0 | – | -110,000 | -100.0% | -0.56% | – |
| Exit | ARIAD PHARMACEUTICALS INCcall | $0 | – | -250,000 | -100.0% | -0.57% | – | |
| Exit | PTC THERAPEUTICS INCcall | $0 | – | -60,000 | -100.0% | -0.63% | – | |
| VNDA | Exit | VANDA PHARMACEUTICALS INC | $0 | – | -150,000 | -100.0% | -0.66% | – |
| ELGX | Exit | ENDOLOGIX INC | $0 | – | -150,000 | -100.0% | -0.72% | – |
| Exit | SPARK THERAPEUTICS INCput | $0 | – | -50,000 | -100.0% | -0.82% | – | |
| T107PS | Exit | WRIGHT MED GROUP INC | $0 | – | -100,000 | -100.0% | -0.83% | – |
| TRNX | Exit | TORNIER N V | $0 | – | -150,000 | -100.0% | -1.20% | – |
| Exit | ABBVIE INCcall | $0 | – | -60,000 | -100.0% | -1.28% | – | |
| Exit | MERCK & CO INC NEWcall | $0 | – | -75,000 | -100.0% | -1.46% | – | |
| MDT | Exit | MEDTRONIC PLC | $0 | – | -75,000 | -100.0% | -1.98% | – |
| MCK | Exit | MCKESSON CORP | $0 | – | -30,000 | -100.0% | -2.18% | – |
| EW | Exit | EDWARDS LIFESCIENCES CORP | $0 | – | -60,000 | -100.0% | -3.36% | – |
| PFE | Exit | PFIZER INC | $0 | – | -300,000 | -100.0% | -3.71% | – |
| Exit | PFIZER INCcall | $0 | – | -400,000 | -100.0% | -4.94% | – | |
| Exit | DEXCOM INCcall | $0 | – | -15,000 | -100.0% | -5.06% | – | |
| ANTM | Exit | ANTHEM INC | $0 | – | -100,000 | -100.0% | -5.51% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-02-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BIOGEN INC | 17 | Q1 2018 | 7.5% |
| ULTRAGENYX PHARMACEUTICAL IN | 17 | Q1 2018 | 6.7% |
| MERCK & CO INC NEW | 16 | Q1 2018 | 5.4% |
| CELGENE CORP | 15 | Q4 2017 | 7.9% |
| AERIE PHARMACEUTICALS INC | 15 | Q4 2017 | 3.3% |
| GILEAD SCIENCES INC | 14 | Q1 2017 | 6.7% |
| ESPERION THERAPEUTICS INC NE | 14 | Q1 2018 | 7.8% |
| SUPERNUS PHARMACEUTICALS INC | 14 | Q4 2017 | 2.8% |
| DERMIRA INC | 14 | Q1 2018 | 2.7% |
| AMGEN INC | 13 | Q1 2017 | 6.5% |
View Iguana Healthcare Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2018-05-15 |
| 13F-HR | 2018-02-14 |
| 13F-HR/A | 2017-11-16 |
| 13F-HR | 2017-11-14 |
| 13F-HR | 2017-08-14 |
| 13F-HR | 2017-05-15 |
| 13F-HR | 2017-02-14 |
| 13F-HR/A | 2016-11-17 |
| 13F-HR | 2016-11-14 |
| 13F-HR/A | 2016-11-04 |
View Iguana Healthcare Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.